Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
J Nucl Med ; 62(5): 679-684, 2021 05 10.
Artículo en Inglés | MEDLINE | ID: mdl-33067338

RESUMEN

This first-in-humans study investigated the safety, biodistribution, and radiation dosimetry of a novel 18F-labeled radiohybrid prostate-specific membrane antigen (rhPSMA) PET imaging agent, 18F-rhPSMA-7.3. Methods: Six healthy volunteers (3 men, 3 women) underwent multiple whole-body PET acquisitions at scheduled time points up to 248 min after the administration of 18F-rhPSMA-7.3 (mean activity, 220; range, 210-228 MBq). PET scans were conducted in 3 separate sessions, and subjects were encouraged to void between sessions. Blood and urine samples were collected for up to 4 h after injection to assess metabolite-corrected radioactivity in whole blood, plasma, and urine. Quantitative measurements of 18F radioactivity in volumes of interest over target organs were determined directly from the PET images at 8 time points, and normalized time-activity concentration curves were generated. These normalized cumulated activities were then inputted into the OLINDA/EXM package to calculate the internal radiation dosimetry and the subjects' effective dose. Results:18F-rhPSMA-7.3 was well tolerated. One adverse event (mild headache, not requiring medication) was considered possibly related to 18F-rhPSMA-7.3. The calculated effective dose was 0.0141 mSv/MBq when using a 3.5-h voiding interval. The organs with the highest mean absorbed dose per unit of administered radioactivity were the adrenals (0.1835 mSv/MBq), the kidneys (0.1722 mSv/MBq), the submandibular glands (0.1479 mSv), and the parotid glands (0.1137 mSv/MBq). At the end of the first scanning session (mean time, 111 min after injection), an average of 7.2% (range, 4.4%-9.0%) of the injected radioactivity of 18F-rhPSMA-7.3 was excreted into urine. Conclusion: The safety, biodistribution, and internal radiation dosimetry of 18F-rhPSMA-7.3 are considered favorable for PET imaging.


Asunto(s)
Antígenos de Superficie/química , Radioisótopos de Flúor/química , Glutamato Carboxipeptidasa II/química , Glutamato Carboxipeptidasa II/farmacocinética , Voluntarios Sanos , Seguridad , Adulto , Antígenos de Superficie/efectos adversos , Femenino , Glutamato Carboxipeptidasa II/efectos adversos , Humanos , Marcaje Isotópico , Masculino , Radiometría , Distribución Tisular
3.
J Infect Dev Ctries ; 11(1): 1-9, 2017 Jan 30.
Artículo en Inglés | MEDLINE | ID: mdl-28141584

RESUMEN

INTRODUCTION: Lyme borreliosis, caused by Borrelia burgdorferi sensu stricto in the United States and by several Borrelia species in Europe and Asia, has a great impact on the health of the global population. There are human vaccines available, such as the outer surface protein A (OspA) vaccine, but still more evidence is needed to verify its function. We investigated the safety, immunogenicity, and efficacy of adjuvanted or non-adjuvanted vaccines containing protective epitopes from Borrelia species OspA serotypes in healthy adults. METHODOLOGY: Seven electronic databases were searched for clinical trials involving vaccine of OspA, with outcome data on safety, immunogenicity, and efficacy. The meta-analysis method was used to compare all vaccination strategies at the same time. RESULTS: Three relevant studies were identified. All were randomized controlled trials (RCTs) or quasi-RCTs. Meta-analysis shows that, compared with low dose, high dose comes with a higher IgG titer with overall effect size of 6.39. For the 30 µg dose, the geometric mean titer was 6918.31, which is statistically significant when compared with 0. With respect to safety, only soreness showed a relatively high incidence of 40% (p < 0.05 when compared with 0, while the other side effects were no difference compared with 0). CONCLUSIONS: The OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified. Instead of stagnating or giving up, further research on improving the vaccine is needed. On the foundation of preliminary studies, we can attempt to develop new vaccines for human use.


Asunto(s)
Antígenos de Superficie/efectos adversos , Antígenos de Superficie/inmunología , Proteínas de la Membrana Bacteriana Externa/efectos adversos , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/efectos adversos , Vacunas Bacterianas/inmunología , Borrelia burgdorferi/inmunología , Lipoproteínas/efectos adversos , Lipoproteínas/inmunología , Enfermedad de Lyme/prevención & control , Adyuvantes Inmunológicos/administración & dosificación , Anticuerpos Antibacterianos/sangre , Antígenos de Superficie/administración & dosificación , Proteínas de la Membrana Bacteriana Externa/administración & dosificación , Vacunas Bacterianas/administración & dosificación , Ensayos Clínicos como Asunto , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Salud Global , Humanos , Inmunoglobulina G/sangre , Lipoproteínas/administración & dosificación , Dolor/inducido químicamente , Dolor/epidemiología , Resultado del Tratamiento
4.
J Nucl Med ; 57(7): 1006-13, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-26795286

RESUMEN

UNLABELLED: The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA. (68)Ga-PSMA-(N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) ((68)Ga-PSMA) PET/CT was used for patient selection and follow-up after PSMA RLT. Hematologic status, renal function, and serum prostate-specific antigen levels were documented before and after therapy. Dosimetry was performed in 30 patients. RESULTS: (177)Lu-PSMA demonstrated high absorbed tumor doses (median, 3.3 mGy/MBq) compared with the levels in normal organs. Parotid glands received higher doses (1.3 mGy/MBq) than kidneys (0.8 mGy/MBq). All patients tolerated the therapy without any acute adverse effects. Except for mild reversible xerostomia in 2 patients, no long-term side effects were observed. There was a small but statistically significant reduction in erythrocyte and leukocyte counts; only the reduction in erythrocyte counts decreased slightly below the reference range. No thrombocytopenia occurred. The severity of pain was significantly reduced in 2 of 6 patients (33.3%). A decrease in prostate-specific antigen levels was noted in 45 of 56 patients (80.4%). Of 25 patients monitored for at least 6 mo after 2 or more PSMA RLT cycles, a molecular response evaluation ((68)Ga-PSMA PET/CT) revealed partial remission in 14, stable disease in 2, and progressive disease in 9 patients. Contrast-enhanced CT revealed partial remission in 5, stable disease in 13, and progressive disease in 7 patients. The median progression-free survival was 13.7 mo, and the median overall survival was not reached during follow-up for 28 mo. CONCLUSION: PSMA RLT with (177)Lu-PSMA is feasible, safe, and effective in end-stage progressive mCRPC with appropriate selection and follow-up of patients by (68)Ga-PSMA PET/CT through application of the concept of theranostics.


Asunto(s)
Antígenos de Superficie/uso terapéutico , Glutamato Carboxipeptidasa II/uso terapéutico , Neoplasias de la Próstata Resistentes a la Castración/radioterapia , Radiofármacos/uso terapéutico , Anciano , Antígenos de Superficie/efectos adversos , Estudios de Cohortes , Dipéptidos/uso terapéutico , Supervivencia sin Enfermedad , Ácido Edético/análogos & derivados , Recuento de Eritrocitos , Isótopos de Galio , Radioisótopos de Galio , Glutamato Carboxipeptidasa II/efectos adversos , Compuestos Heterocíclicos con 1 Anillo/uso terapéutico , Humanos , Recuento de Leucocitos , Lutecio , Masculino , Metástasis de la Neoplasia , Oligopéptidos , Compuestos Organometálicos/uso terapéutico , Dolor/etiología , Dolor/radioterapia , Selección de Paciente , Tomografía de Emisión de Positrones , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata Resistentes a la Castración/diagnóstico por imagen , Radiometría , Radiofármacos/efectos adversos , Resultado del Tratamiento
5.
Clin Vaccine Immunol ; 21(11): 1490-9, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25185574

RESUMEN

Lyme borreliosis (LB) patients who recover, as well as previously infected asymptomatic individuals, remain vulnerable to reinfection with Borrelia burgdorferi sensu lato. There is limited information available about the use of OspA vaccines in this population. In this study, a randomized double-blind phase I/II trial was performed to investigate the safety and immunogenicity of a novel multivalent OspA vaccine in healthy adults who were either seronegative or seropositive for previous B. burgdorferi sensu lato infection. The participants received three monthly priming immunizations with either 30 µg or 60 µg alum-adjuvanted OspA antigen and a booster vaccination either 6 months or 9 to 12 months after the first immunization. The antibody responses to the six OspA serotypes included in the vaccine were evaluated. Adverse events were predominantly mild and transient and were similar in the seronegative and seropositive populations. Substantial enzyme-linked immunosorbent assay (ELISA) and surface-binding antibody responses against all six OspA antigens were induced after the primary immunization schedule in both populations, and they were substantially increased with both booster schedules. The antibody responses induced by the two doses were similar in the seronegative population, but there was a significant dose response in the seropositive population. These data indicate that the novel multivalent OspA vaccine is well tolerated and immunogenic in individuals previously infected with B. burgdorferi sensu lato. (This study is registered at ClinicalTrials.gov under registration no. NCT01504347.).


Asunto(s)
Antígenos de Superficie/efectos adversos , Antígenos de Superficie/inmunología , Proteínas de la Membrana Bacteriana Externa/efectos adversos , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/efectos adversos , Vacunas Bacterianas/inmunología , Grupo Borrelia Burgdorferi/inmunología , Lipoproteínas/efectos adversos , Lipoproteínas/inmunología , Enfermedad de Lyme/inmunología , Enfermedad de Lyme/prevención & control , Vacunación/efectos adversos , Vacunación/métodos , Adyuvantes Inmunológicos/administración & dosificación , Adolescente , Adulto , Anciano , Compuestos de Alumbre/administración & dosificación , Anticuerpos Antibacterianos/sangre , Antígenos de Superficie/administración & dosificación , Proteínas de la Membrana Bacteriana Externa/administración & dosificación , Vacunas Bacterianas/administración & dosificación , Método Doble Ciego , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Lipoproteínas/administración & dosificación , Masculino , Persona de Mediana Edad , Adulto Joven
11.
Lancet Infect Dis ; 13(8): 680-9, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23665341

RESUMEN

BACKGROUND: Lyme borreliosis is caused by Borrelia burgdorferi sensu stricto in the USA and by several Borrelia species in Europe and Asia, but no human vaccine is available. We investigated the safety and immunogenicity of adjuvanted and non-adjuvanted vaccines containing protective epitopes from Borrelia species outer surface protein A (OspA) serotypes in healthy adults. METHODS: Between March 1, 2011, and May 8, 2012, we did a double-blind, randomised, dose-escalation phase 1/2 study at four sites in Austria and Germany. Healthy adults aged 18-70 years who were seronegative for B. burgdorferi sensu lato were eligible for inclusion. Participants were recruited sequentially and randomly assigned to one of six study groups in equal ratios via an electronic data capture system. Participants and investigators were masked to group allocation. Participants received three vaccinations containing 30 µg, 60 µg, or 90 µg OspA antigen with or without an adjuvant, with intervals of 28 days, and a booster 9-12 months after the first immunisation. The coprimary endpoints were the frequency and severity of injection-site and systemic reactions within 7 days of each vaccination, and the antibody responses to OspA serotypes 1-6, as established by ELISA. This study is registered with ClinicalTrials.gov, number NCT01504347. FINDINGS: 300 participants were randomly assigned: 151 to adjuvanted vaccines (50 to 30 µg, 51 to 60 µg, and 50 to 90 µg doses), and 149 to non-adjuvanted vaccines (50 to 30 µg, 49 to 60 µg, and 50 to 90 µg doses). Adverse reactions were predominantly mild, and no vaccine-related serious adverse events were reported. The risk of systemic reactions (risk ratio 0·54 [95% CI 0·41-0·70]; p<0·0001) and of moderate or severe systemic reactions (0·35 [0·13-0·92]; p=0·034) was significantly lower for adjuvanted than non-adjuvanted formulations. The 30 µg adjuvanted formulation had the best tolerability profile; only headache (five [10%, 95% CI 4-20] of 50), injection-site pain (16 [32%, 21-45]), and tenderness (17 [34%, 23-47]) affected more than 6% of patients. All doses and formulations induced substantial mean IgG antibody titres against OspA serotypes 1-6 after the first three vaccinations (range 6944-17,321) and booster (19,056-32,824) immunisations. The 30 µg adjuvanted formulation induced the highest antibody titres after the booster: range 26,143 (95% CI 18,906-36,151) to 42,381 (31,288-57,407). INTERPRETATION: The novel multivalent OspA vaccine could be an effective intervention for prevention of Lyme borreliosis in Europe and the USA, and possibly worldwide. Larger confirmatory formulation studies will need to be done that include individuals seropositive for Borrelia burgdorferi sensu lato before placebo-controlled phase 3 efficacy studies can begin. FUNDING: Baxter.


Asunto(s)
Adyuvantes Inmunológicos/efectos adversos , Antígenos de Superficie/efectos adversos , Antígenos de Superficie/inmunología , Proteínas de la Membrana Bacteriana Externa/efectos adversos , Proteínas de la Membrana Bacteriana Externa/inmunología , Vacunas Bacterianas/efectos adversos , Vacunas Bacterianas/inmunología , Borrelia burgdorferi/inmunología , Lipoproteínas/efectos adversos , Lipoproteínas/inmunología , Vacunas contra Enfermedad de Lyme/efectos adversos , Vacunas contra Enfermedad de Lyme/inmunología , Adulto , Método Doble Ciego , Femenino , Cefalea/inducido químicamente , Humanos , Inmunoglobulina G/sangre , Masculino , Persona de Mediana Edad , Dolor/inducido químicamente , Adulto Joven
12.
Fish Shellfish Immunol ; 35(2): 375-81, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23659996

RESUMEN

Large yellow croaker (Pseudosciaena crocea), a major marine fish aquacultured in the southeastern coastal region of China, has become endangered by the pathogen Pseudomonas putida in recent years. P. putida infections occur in low water temperatures when fish reduce food intake, thus oral antibiotic administration is not practical. Therefore, vaccination may be the only method to prevent the infection. In the present study, main surface antigens of P. putida, including lipopolysaccharide (LPS), outer membrane proteins (OMP), extracellular biofilm polysaccharide (EPS), and formalin-killed cell (FKC) bacterin, were prepared and the fish vaccinated. On post-immunization day 28, serum antibody titers, phagocytic responses of leukocytes, and lysozyme activities of the fish were evaluated. The efficiency of vaccination was tested by artificial challenge via intraperitoneal injection of live bacteria on post-immunization day 28 and 35, respectively. The results showed that although significant humoral and innate immune responses were elicited in all vaccination groups, the challenge produced similar poor protection in both tests, with a relative percent survival (RPS) of 0-40%. Although the EPS group showed a complete lack of protection, LPS reached the highest RPS value (40%), suggesting that LPS may be involved in protection immunity against the pathogen. Further analysis of the ultra-structures of tissues from infected fish via TEM revealed macrophage survival and intracellular replication ability of the pathogen. New strategies for development might put more emphasis on efficient clearance of intracellular bacteria. The present study is the first to report vaccination against the fish pathogen P. putida and the first investigation of intracellular survival of this pathogen in host macrophages.


Asunto(s)
Antígenos Bacterianos/efectos adversos , Vacunas Bacterianas/efectos adversos , Enfermedades de los Peces/prevención & control , Perciformes , Infecciones por Pseudomonas/veterinaria , Pseudomonas putida/inmunología , Animales , Antígenos Bacterianos/administración & dosificación , Antígenos de Superficie/administración & dosificación , Antígenos de Superficie/efectos adversos , Proteínas de la Membrana Bacteriana Externa/fisiología , Vacunas Bacterianas/administración & dosificación , Enfermedades de los Peces/inmunología , Enfermedades de los Peces/microbiología , Inmunidad Innata , Lipopolisacáridos/fisiología , Polisacáridos Bacterianos/fisiología , Infecciones por Pseudomonas/inmunología , Infecciones por Pseudomonas/microbiología , Infecciones por Pseudomonas/prevención & control , Vacunación/veterinaria
14.
Int J Risk Saf Med ; 23(2): 89-96, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21673416

RESUMEN

A wide range of neurological complications have been reported via the medical literature and the VAERS system after vaccination with recombinant outer surface protein A (OspA) of Borrelia. To explore this issue, 24 patients reporting neurological adverse events (AE) after vaccination with Lymerix, out of a group of 94 patients reporting adverse events after Lymerix vaccination, were examined for causation. Five reports of cerebral ischemia, two transient Ischemic attacks, five demyelinating events, two optic neuritis, two reports of transverse myelitis, and one non-specific demyelinating condition are evaluated in this paper. Caution is raised on not actively looking for neurologic AE, and for not considering causation when the incidence rate is too low to raise a calculable difference to natural occurence.


Asunto(s)
Antígenos de Superficie/efectos adversos , Proteínas de la Membrana Bacteriana Externa/efectos adversos , Vacunas Bacterianas/efectos adversos , Borrelia burgdorferi/inmunología , Lipoproteínas/efectos adversos , Enfermedad de Lyme/prevención & control , Sistema Nervioso/efectos de los fármacos , Vacunación/efectos adversos , Sistemas de Registro de Reacción Adversa a Medicamentos , Antígenos de Superficie/administración & dosificación , Proteínas de la Membrana Bacteriana Externa/administración & dosificación , Vacunas Bacterianas/administración & dosificación , Isquemia Encefálica/etiología , Enfermedades Desmielinizantes/etiología , Femenino , Humanos , Lipoproteínas/administración & dosificación , Enfermedad de Lyme/epidemiología , Masculino , Persona de Mediana Edad , Neuritis Óptica/etiología , Medición de Riesgo , Estados Unidos/epidemiología , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/efectos adversos
15.
PLoS One ; 6(2): e14626, 2011 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-21347224

RESUMEN

BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secondary goal was to characterize the immune responses. METHODS: Firstly 32 HBV e antigen negative (eAg(-)) participants were randomly assigned to one of four groups: to receive vaccines alone, lamivudine (3TC) alone, both, or neither. Later 16 eAg(+) volunteers in two groups received either 3TC alone or both 3TC and vaccines. Finally, 12 eAg(-) and 12 eAg(+) subjects were enrolled into higher-dose treatment groups. Healthy but chronically HBV-infected males between the ages of 15-25 who lived in the western part of The Gambia were eligible. Participants in some groups received 1 mg or 2 mg of pSG2.HBs intramuscularly twice followed by 5×10(7) pfu or 1.5×10(8) pfu of MVA.HBs intradermally at 3-weekly intervals with or without concomitant 3TC for 11-14 weeks. Intradermal rabies vaccine was administered to a negative control group. Safety was assessed clinically and biochemically. The primary measure of efficacy was a quantitative PCR assay of plasma HBV. Immunity was assessed by IFN-γ ELISpot and intracellular cytokine staining. RESULTS: Mild local and systemic adverse events were observed following the vaccines. A small shiny scar was observed in some cases after MVA.HBs. There were no significant changes in AST or ALT. HBeAg was lost in one participant in the higher-dose group. As expected, the 3TC therapy reduced viraemia levels during therapy, but the prime-boost vaccine regimen did not reduce the viraemia. The immune responses were variable. The majority of IFN-γ was made by antigen non-specific CD16(+) cells (both CD3(+) and CD3(-)). CONCLUSIONS: The vaccines were well tolerated but did not control HBV infection. TRIAL REGISTRATION: ISRCTN ISRCTN67270384.


Asunto(s)
Virus de la Hepatitis B/inmunología , Hepatitis B/prevención & control , Vacunas de ADN/efectos adversos , Vacunas de ADN/inmunología , Virus Vaccinia/genética , Proteínas Virales/efectos adversos , Proteínas Virales/inmunología , Adolescente , Adulto , Antígenos de Superficie/efectos adversos , Antígenos de Superficie/genética , Antígenos de Superficie/inmunología , Enfermedad Crónica/prevención & control , Hepatitis B/tratamiento farmacológico , Hepatitis B/inmunología , Hepatitis B/metabolismo , Antígenos e de la Hepatitis B/metabolismo , Virus de la Hepatitis B/fisiología , Humanos , Inmunidad Celular/inmunología , Interferón gamma/biosíntesis , Interferón gamma/metabolismo , Lamivudine/uso terapéutico , Masculino , Cumplimiento de la Medicación/estadística & datos numéricos , Seguridad , Pruebas Serológicas , Vacunación/efectos adversos , Vacunas de ADN/genética , Carga Viral/inmunología , Proteínas Virales/genética , Adulto Joven
17.
Vaccine ; 23(24): 3131-8, 2005 May 02.
Artículo en Inglés | MEDLINE | ID: mdl-15837212

RESUMEN

Plasmodium vivax is responsible for the majority of malaria cases outside of Africa, and results in substantial morbidity. Transmission blocking vaccines are a potentially powerful component of a multi-faceted public health approach to controlling or eliminating malaria. We report the first phase 1 clinical trial of a P. vivax transmission blocking vaccine in humans. The Pvs25H vaccine is a recombinant protein derived from the Pvs25 surface antigen of P. vivax ookinetes. The protein was expressed in Saccharomyces cerevisiae, purified, and adsorbed onto Alhydrogel. Ten volunteers in each of three dose groups (5, 20, or 80 microg) were vaccinated by intramuscular injection in an open-label study at 0, 28 and 180 days. No vaccine-related serious adverse events were observed. The majority of adverse events causally related to vaccination were mild or moderate in severity. Injection site tenderness was the most commonly observed adverse event. Anti-Pvs25H antibody levels measured by ELISA peaked after the third vaccination. Vaccine-induced antibody is functionally active as evidenced by significant transmission blocking activity in the membrane feeding assay. Correlation between antibody concentration and degree of inhibition was observed. Pvs25H generates transmission blocking immunity in humans against P. vivax demonstrating the potential of this antigen as a component of a transmission blocking vaccine.


Asunto(s)
Antígenos de Protozoos/uso terapéutico , Antígenos de Superficie/uso terapéutico , Vacunas contra la Malaria/uso terapéutico , Malaria Vivax/prevención & control , Malaria Vivax/transmisión , Adolescente , Adulto , Animales , Antígenos de Protozoos/efectos adversos , Antígenos de Superficie/efectos adversos , Culicidae/inmunología , Culicidae/parasitología , Relación Dosis-Respuesta Inmunológica , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Esquemas de Inmunización , Vacunas contra la Malaria/efectos adversos , Masculino , Persona de Mediana Edad , Dinámicas no Lineales , Vacunas Sintéticas/efectos adversos , Vacunas Sintéticas/uso terapéutico
18.
J Peripher Nerv Syst ; 9(3): 165-7, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15363064

RESUMEN

Neurological syndromes that follow vaccination or infection are often attributed to autoimmune mechanisms. We report six patients who developed neuropathy or cognitive impairment, within several days to 2 months, following vaccination with the OspA antigen of Borrelia burgdorferi. Two of the patients developed cognitive impairment, one chronic inflammatory demyelinating polyneuropathy (CIDP), one multifocal motor neuropathy, one both cognitive impairment and CIDP, and one cognitive impairment and sensory axonal neuropathy. The patients with cognitive impairment had T2 hyperintense white matter lesions on magnetic resonance imaging. The similarity between the neurological sequelae observed in the OspA-vaccinated patients and those with chronic Lyme disease suggests a possible role for immune mechanisms in some of the manifestations of chronic Lyme disease that are resistant to antibiotic treatment.


Asunto(s)
Antígenos de Superficie/efectos adversos , Proteínas de la Membrana Bacteriana Externa/efectos adversos , Borrelia burgdorferi/química , Trastornos del Conocimiento/etiología , Lipoproteínas/efectos adversos , Enfermedades del Sistema Nervioso Periférico/etiología , Vacunación/efectos adversos , Adulto , Vacunas Bacterianas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante
20.
Int J Gynaecol Obstet ; 78(2): 121-6, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12175712

RESUMEN

OBJECTIVE: To establish whether primipaternity and duration of unprotected sexual cohabitation is associated with an increased risk of pre-eclampsia. METHOD: At a tertiary referral center, the study had a case and control group of 60 multigravid women each, as well as a case and control group of 50 primigravid women each. Information was compiled by means of a confidential questionnaire. RESULT: After multiple logistic regression analysis using age, smoking, hypertension in previous pregnancies, change of paternity and duration of unprotected sexual cohabitation as predictors, the regression coefficients for change of paternity and sexual cohabitation of longer than 6 months in multigravid women were -0.4 (P = 0.15) and -1.4 (P = 0.03), respectively. CONCLUSION: Multigravid women with a period of unprotected sexual cohabitation of longer than 6 months had a decreased risk of pre-eclampsia. Primipaternity was not a significant risk factor for pre-eclampsia.


Asunto(s)
Antígenos de Superficie/efectos adversos , Antígenos de Superficie/inmunología , Paternidad , Preeclampsia/etiología , Preeclampsia/inmunología , Sexo Seguro , Parejas Sexuales , Espermatozoides/inmunología , Adulto , Femenino , Número de Embarazos/inmunología , Humanos , Masculino , Valor Predictivo de las Pruebas , Embarazo , Análisis de Regresión , Factores de Riesgo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...